What is NDC 87211-030?

87211-030 is the product NDC for Lisraya (brepocitinib), Brepocitinib tosylate 30 mg/1 tablet, film coated, listed with the FDA by Priovant Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Priovant Therapeutics, Inc., NDC labeler code 87211. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Lisraya?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Lisraya NDC 87211-030 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)87211-030Labeler and product segments. Claims need a package NDC.

Product NDC at billing width87211-0030Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
87211-030-30	87211003030	1 BOTTLE in 1 CARTON (87211-030-30) / 30 TABLET, FILM COATED in 1 BOTTLEMarketed from Aug 27, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lisraya
Generic name (nonproprietary): brepocitinib
Active ingredients: Brepocitinib tosylate — 30 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Priovant Therapeutics, Inc.NDC labeler code 87211
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 220106
Marketing start: Aug 27, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 87211-030_4ea28f02-7a6c-4e71-86ba-8c516f6d9323SPL ID 4ea28f02-7a6c-4e71-86ba-8c516f6d9323SPL set ID 5023a17b-e96a-67d4-e063-6394a90a14a7RxCUI 2751541, 2751547UNII C960DPP15OUPC 0387211030300

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N487211003030 followed by a unit qualifier and the quantity

Package 87211-0030-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 28, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

LISRAYA is indicated for the treatment of dermatomyositis in adult patients. LISRAYA is a Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of dermatomyositis in adult patients. ( 1 ) Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs. Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 87211-030

What is NDC 87211-030?: 87211-030 is the product NDC for Lisraya (brepocitinib), Brepocitinib tosylate 30 mg/1 tablet, film coated, listed with the FDA by Priovant Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Lisraya (Brepocitinib).
What is the active ingredient?: Brepocitinib tosylate.
Who is the labeler?: Priovant Therapeutics, Inc., NDC labeler code 87211. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Lisraya?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Lisraya (Brepocitinib) NDC 87211-030